Browse > Article
http://dx.doi.org/10.5351/KJAS.2021.34.2.255

Analysis of stage III stomach cancer using the restricted mean survival time  

Kim, Bitna (Department of Statistics, Kangwon National University)
Lee, Minjung (Department of Statistics, Kangwon National University)
Publication Information
The Korean Journal of Applied Statistics / v.34, no.2, 2021 , pp. 255-266 More about this Journal
Abstract
The purpose of this study is to compare the effects of treatment on stage III stomach cancer data obtained from the SEER program of the National Cancer Institute and to identify the significant risk factors for the survival rates of stage III stomach cancer. Since the proportional hazards assumption was violated for treatment, we used the restricted mean survival time as an alternative to the proportional hazards model. The restricted mean survival time was estimated using pseudo-observations, and the effects of treatment were compared using a test statistic based on the estimated restricted mean survival times. We conducted the regression analysis using a generalized linear model to investigate the significant predictors for the restricted mean survival time of patients with stage III stomach cancer. We found that there was a significant difference between the restricted mean survival times of treatment groups. Age at diagnosis, race, substage, grade, tumor size, surgery, and treatment were significant predictors for the restricted mean survival time of patients with stage III stomach cancer. Surgery was the most significant predictor for increasing the restricted mean survival time of patients with stage III stomach cancer.
Keywords
pseudo-observations; restricted mean survival time; stomach cancer; survival analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Grambsch P and Therneau T (1994). Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, 81 ,515-526.   DOI
2 Liang KY and Zeger SL (1986). Longitudinal data analysis using generalized linear models, Biometrika, 73, 13-22.   DOI
3 Surveillance, Epidemiology, and End results (SEER) program (www.seer.cancer.gov) SEER*Stat Database : Incidence - SEER 18 Regs custom data (with additional treatment fields), Nov 2018 Sub (1975-2016 varying) - Linked to county attributes - total US, 1969-2017 counties, national cancer institute, DCCPS, Surveillance research program, released April 2019, based on the November 2018 submission.
4 Irwin JO (1949). The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice, The Journal of Hygiene, 47, 188-189.   DOI
5 Tian L, Zhao L, and Wei LJ (2014). Predicting the Restricted mean event time with the subject's baseline covariates in survival analysis, Biostatistics, 15, 222-233.   DOI
6 Andersen PK, Hansen MG, and Klein JP (2004). Regression analysis of restricted mean survival time based on pseudo-observations, Lifetime Data Analysis, 10, 335-350.   DOI
7 Andersen PK and Perme MP (2010). Pseudo-observations in survival analysis, Statistical Methods in Medical Research, 19, 71-99.   DOI
8 Chen PY and Tsiatis AA (2001). Causal inference on the difference of the restricted mean lifetime between two groups, Biometrics, 57, 1030-1038.   DOI
9 Cox DR (1972). Regression models and life-tables (with discussion), Journal of Royal Statistical Society, Series A, 34, 187-220.
10 Guo C and Liang Y (2019). Analyzing restricted mean survival time using SAS/STAT, SAS Institute Inc., Cary, NC.
11 Royston P and Parmar MK (2011). The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt, Statistics in Medicine, 30, 2409-2421.   DOI
12 Zeger SL and Liang KY (1986). Longitudinal data analysis for discrete and continuous outcomes, Biometrics, 42, 121-130.   DOI
13 Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, and Wei LJ (2012). Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study, Clinical Trials, 9, 570-577.   DOI
14 Korea Central Cancer Registry (2019). National cancer center, Annual report of cancer statistics in Korea in 2017, Ministry of health and welfare.
15 National Cancer Information Center (2019). Cancer information service. from: https://www.cancer.go.kr/
16 Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations, Journal of the American Statistical Association, 53, 457-481.   DOI
17 Nemes S, Bulow E, and Gustavsson A (2020). A brief overview of restricted mean survival time estimators and associated variances, MDPI Stats, 3, 107-119.
18 Prentice RL (1978). Linear rank tests with right censored data, Biometrike, 65, 167-180.   DOI
19 Ruhl J, Ward E, Hofferkamp J, et al (2019). Grade Manual. NAACCR, Springfield, IL 62704-4194.
20 Schoenfeld D (1982). Partial residuals for the proportional hazards regression model, Biometrika, 69, 239-241.   DOI